Three new iminosugar-containing KRN7000 （also referred to as α-GalCer） analogues were designed and syn- thesized. In the design, the galactose moiety of KRN7000 was replaced by iminosugars and the iminosugar struc-...Three new iminosugar-containing KRN7000 （also referred to as α-GalCer） analogues were designed and syn- thesized. In the design, the galactose moiety of KRN7000 was replaced by iminosugars and the iminosugar struc- tures were connected with ceramide in different manners with a C-glycosidic bond instead of the O-glycosidic bond. To our knowledge, this is the first report in which iminosugars are incorporated in KRN7000 structure modifica- tions. The synthetic compounds were evaluated for their ability to stimulate cytokine release. The results may benefit better understanding of structure-activity relationships and facilitate future design of more KRNT000 derivatives.展开更多
基金This work was financially supported by the National Natural Science Foundation of China （No. 21232002）.
文摘Three new iminosugar-containing KRN7000 （also referred to as α-GalCer） analogues were designed and syn- thesized. In the design, the galactose moiety of KRN7000 was replaced by iminosugars and the iminosugar struc- tures were connected with ceramide in different manners with a C-glycosidic bond instead of the O-glycosidic bond. To our knowledge, this is the first report in which iminosugars are incorporated in KRN7000 structure modifica- tions. The synthetic compounds were evaluated for their ability to stimulate cytokine release. The results may benefit better understanding of structure-activity relationships and facilitate future design of more KRNT000 derivatives.
